Clindamycin

For the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Federal law restricts this drug to use by or on the order of a licensed veterinarian

ClindaMed™ Oral Drops

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or (S. intermedius), deep wounds and abscesses due to susceptible strains of (Bacteroides fragilis, (Prevotella melaninogenicus, (Fusobacterium necrophorum, and (Clostridium perfringens; dental infections due to susceptible strains of (S. aureus, (B. fragilis, (P. melaninogenicus, (F. necrophorum, and (C. perfringens; and osteomyelitis due to susceptible strains of (S. aureus, (B. fragilis, (P. melaninogenicus, (F. necrophorum, and (C. perfringens.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clinsol®

For use in dogs for treatment of soft tissue infections (wounds and abscesses) and dental infections caused by susceptible strains of Staphylococcus aureus and for soft tissue infections (deep wounds and abscesses) and dental infections caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

For treatment of osteomyelitis caused by susceptible strains of Staphylococcus aureus, and osteomyelitis caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

Aerobic bacteria: Treatment of soft tissue infections (wounds and abscesses) and dental infections caused by or associated with susceptible strains of Staphylococcus aureus, S. intermedius, and Streptococcus species Anaerobic bacteria: Treatment of soft tissue infections (deep wounds and abscesses) and dental infections caused by or associated with susceptible strains of Clostridium perfringens and Bacteroides fragilis.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Staphylococcus aureus, S. intermedius, Streptococcus spp.; deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis; and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus spp., C. perfringens, and B. fragilis.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clinsol®

Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and abscesses due to Clostridium perfringens and Bacteroides fragilis. Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

Federal law restricts this drug to use by or on the order of a licensed veterinarian

ClindaMed™ Oral Drops

ANTIROBE (brand of clindamycin hydrochloride) Capsules (for use in dogs only) and AQUADROPS oral solution (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Cats: Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and abscesses due to Clostridium perfringens and Bacteroides fragilis. Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

Antirobe Aquadrops®

ANTIROBE (brand of clindamycin hydrochloride) Capsules (for use in dogs only) and AQUADROPS Liquid (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Cats: Deep wounds and abscesses due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and infections due to Clostridium perfringens and Bacteroides fragilis. Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

Antirobe®clindamycin capsules (as clindamycin hydrochloride) Antirobe® Aquadrops®clindamycin oral solution (as clindamycin hydrochloride)

ZydaClin™ Tablets (clindamycin hydrochloride tablets) (for use in dogs only) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below: Dogs: Skin infections (wounds and abscesses) due to: coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bateroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Dental infections due to Staphyloccus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

ZydaClin™ Tablets (clindamycin hydrochloride tablets)

Clindamycin Hydrochloride Oral Drops (for use in dogs and cats) is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

ZydaClin™ ​ ​

Absorption Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract. Dog Serum Levels Serum levels at or above 0.5 μg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs. Clindamycin Serum Concentrations 2.5 mg/lb (5.5 mg/kg) After B.I.D. Oral Dose of Clindamycin Hydrochloride Capsules to Dogs Metabolism and Excretion Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-demethyl clindamycin and clindamycin sulfoxide. Site and Mode of Action Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level. Microbiology Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal sub-unit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs in the United States are presented in Table 1. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the Clinical and Laboratory Standards Institute (CLSI). Table 1. Clindamycin MIC Values (μg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-991 Organism Number of Isolates MIC50 MIC85 MIC90 Range Soft Tissue/Wound2 Staphylococcus aureus 17 0.5 0.5 ≥ 4.0 0.25 - ≥ 4.0 Staphylococcus intermedius 28 0.25 0.5 ≥ 4.0 0.125 - ≥ 4.0 Staphylococcus spp. 18 0.5 0.5 ≥ 4.0 0.25 - ≥ 4.0 Beta-hemolytic streptococci 46 0.5 0.5 ≥ 4.0 0.25 - ≥ 4.0 Streptococcus spp. 11 0.5 ≥ 4.0 ≥ 4.0 0.25 - ≥ 4.0 Osteomyelitis/Bone3 Staphylococcus aureus 20 0.5 0.5 0.5 0.54 Staphylococcus intermedius 15 0.5 ≥ 4.0 ≥ 4.0 0.25 - ≥ 4.0 Staphylococcus spp. 18 0.5 ≥ 4.0 ≥ 4.0 0.25 - ≥ 4.0 Beta-hemolytic streptococci 21 0.5 2.0 2.0 0.25 - ≥ 4.0 Streptococcus spp. 21 ≥ 4.0 ≥ 4.0 ≥ 4.0 0.25 - ≥ 4.0 Dermal/Skin5 Staphylococcus aureus 25 0.5 ≥ 4.0 ≥ 4.0 0.25 - ≥ 4.0 Staphylococcus intermedius 48 0.5 ≥ 4.0 ≥ 4.0 0.125 - ≥ 4.0 Staphylococcus spp. 32 0.5 ≥ 4.0 ≥ 4.0 0.25 - ≥ 4.0 Beta-hemolytic streptococci 17 0.5 0.5 0.5 0.25 - 0.5 1The correlation between the in vitro susceptibility data and clinical response has not been determined. 2Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass 3Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon 4No range, all isolates yielded the same value 5Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision, lip

Clindamycin Hydrochloride Tablets

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract. Dog Serum Levels: Serum levels at or above 0.5 μg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs. Metabolism and Excretion: Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-demethyl clindamycin and clindamycin sulfoxide. Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level. Microbiology: Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal sub-unit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs in the United States are presented in Table 1. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the Clinical and Laboratory Standards Institute (CLSI).

CLINTABS® (clindamycin hydrochloride tablets)

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

ZydaClin™ ​ ​

ANTIROBE Capsules and ANTIROBE AQUADROPS oral solution are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

Antirobe®clindamycin capsules (as clindamycin hydrochloride) Antirobe® Aquadrops®clindamycin oral solution (as clindamycin hydrochloride)

Clindamycin Hydrochloride Capsules, USP are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin. Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

Clindamycin Hydrochloride Capsules, USP

Not for use in humans. Keep out of reach of children. To obtain a Safety Data Sheet(s), contact First Priority, Inc. at (800) 650-4899 or www.prioritycare.com. Keep Clindamycin Hydrochloride Oral Drops in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

ZydaClin™ ​ ​

Not for use in humans. Keep out of reach of children. To obtain a Safety Data Sheet(s), contact First Priority, Inc. at (800) 650-4899 or www.pivetalvet.com. Keep Clindamycin Hydrochloride Oral Drops in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

CLINDA-GUARD® DROPS

Not for use in humans. Keep out of reach of children. To obtain a Safety Data Sheet(s), contact Covetrus® North America at (855) 724-3461 or www.covetrus.com. Keep Clindamycin HCl Oral drops in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Clindamycin HClOral drops

Not for use in humans. Keep out of reach of children. To obtain a Safety Data Sheet(s), contact Vedco, Inc. at (888) 708-3326 or www.vedco.com. Keep ClindaCure® in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

ClindaCure® ​ (clindmycin hydrochloride liquid)

Approved for use in dogs and cats. Equivalent to 25 mg/mL clindamycin NET CONTENTS: 20 mL (0.68 fl oz) Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not For Use in Humans Keep Out of Reach of Children

ClindaCure® ​ (clindmycin hydrochloride liquid)

Keep out of reach of children. Not for human use. Keep Clindamycin Hydrochloride Tablets in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Clindamycin Hydrochloride Tablets

(clindamycin hydrochloride oral solution) Approved for use in dogs and cats. Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Drops

(clindamycin hydrochloride oral solution) Approved for use in dogs and cats. Equivalent to 25 mg per mL clindamycin

ZydaClin™ ​ ​

Keep out of reach of children. Not for human use.

Antirobe®clindamycin capsules (as clindamycin hydrochloride) Antirobe® Aquadrops®clindamycin oral solution (as clindamycin hydrochloride)

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact First Priority, Inc. at (800) 650-4899 or www.prioritycare.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

ZydaClin™ ​ ​

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Covetrus® North America at (855) 724-3461 or www.covetrus.com.. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

Clindamycin HClOral drops

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea. To report a suspected adverse reaction or to request a material safety data sheet (MSDS), call 1-800-650-4899.

ZydaClin™ ​ ​

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea. To report adverse reactions or a suspected adverse reaction, call 1-800-338-3659.

CLINTABS® (clindamycin hydrochloride tablets)

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea. To report a suspected adverse reaction call 1-844-227-6687 (1-844-2-CRONUS)

Clindamycin Hydrochloride Capsules, USP

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

Clindamycin Hydrochloride Tablets

Wounds, abscesses, and dental infections: 2.5 to 15 milligrams per pound of body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clintabs®

Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound (/lb) body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

Oral

Clindamycin Hydrochloride Tablets

Wounds abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

5.0 to 10.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days (11 to 22 milligrams per kilogram of body weight per day).

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clinsol®

5.0 to 15.0 mg/lb body weight every 24 hours for a maximum of 14 days

Oral

Federal law restricts this drug to use by or on the order of a licensed veterinarian

ClindaMed™ Oral Drops

Dogs: Infected Wounds, Abscesses, and Dental Infections Oral: 2.5-15.0 mg/lb body weight every 12 hours Duration: Treatment with ANTIROBE products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen Dosage Schedule Capsules ANTIROBE 25 mg, administer 1-6 capsules every 12 hours for each 10 pounds of body weight. ANTIROBE 75 mg, administer 1-6 capsules every 12 hours for each 30 pounds of body weight. ANTIROBE 150 mg, administer 1-6 capsules every 12 hours for each 60 pounds of body weight. Oral Solution ANTIROBE AQUADROPS, administer 1-6 mL/10 lbs body weight every 12 hours. Dogs: Osteomyelitis Oral: 5.0-15.0 mg/lb body weight every 12 hours Duration: Treatment with ANTIROBE is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen. Dosage Schedule: Capsules ANTIROBE 25 mg, administer 2-6 capsules every 12 hours for each 10 pounds of body weight. ANTIROBE 75 mg, administer 2-6 capsules every 12 hours for each 30 pounds of body weight. ANTIROBE 150 mg, administer 2-6 capsules every 12 hours for each 60 pounds of body weight. Oral Solution ANTIROBE AQUADROPS, administer 2-6 mL/10 lbs body weight every 12 hours. Cats: Infected Wounds, Abscesses, and Dental Infections 5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition. Duration: Treatment with ANTIROBE AQUADROPS oral solution may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen Dosage schedule: ANTIROBE AQUADROPS, to provide 5.0 mg/lb, administer 1 mL/5 lbs body weight once every 24 hours; to provide 15.0 mg/lb, administer 3 mL/5 lbs body weight once every 24 hours.

ORAL

Antirobe®clindamycin capsules (as clindamycin hydrochloride) Antirobe® Aquadrops®clindamycin oral solution (as clindamycin hydrochloride)

Dogs: Infected Wounds, Abscesses, and Dental Infections Oral: 2.5-15.0 mg/lb body weight every 12 hours. Duration: Treatment with Clindamycin Hydrochloride Capsules, USP may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen. Dosage Schedule Capsules Clindamycin Hydrochloride Capsules, USP 25 mg, administer 1-6 capsules every 12 hours for each 10 pounds of body weight. Clindamycin Hydrochloride Capsules, USP 75 mg, administer 1 -6 capsules every 12 hours for each 30 pounds of body weight. Clindamycin Hydrochloride Capsules, USP 150 mg, administer 1-6 capsules every 12 hours for each 60 pounds of body weight. Clindamycin Hydrochloride Capsules, USP 300 mg, administer 1-6 capsules every 12 hours for each 120 pounds of body weight. Dogs: Osteomyelitis Oral: 5.0-15.0 mg/lb body weight every 12 hours. Duration: Treatment with Clindamycin Hydrochloride Capsules is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen. Dosage Schedule: Capsules Clindamycin Hydrochloride Capsules, USP 25 mg, administer 2-6 capsules every 12 hours for each 10 pounds of body weight. Clindamycin Hydrochloride Capsules, USP 75 mg, administer 2 -6 capsules every 12 hours for each 30 pounds of body weight. Clindamycin Hydrochloride Capsules, USP 150 mg, administer 2-6 capsules every 12 hours for each 60 pounds of body weight. Clindamycin Hydrochloride Capsules, USP 300 mg, administer 2-6 capsules every 12 hours for each 120 pounds of body weight

ORAL

Clindamycin Hydrochloride Capsules, USP

Dogs: Infected Wounds, Abscesses and Dental Infections Oral: 2.5 - 15.0 mg/lb body weight every 12 hours. Duration: Treatment with Clindamycin Hydrochloride Oral Drops products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen. Dosage Schedule: Oral Solution Clindamycin Hydrochloride Oral Drops, administer 1-6 mL/10 lbs body weight every 12 hours. Dogs: Osteomyelitis Oral: 5.0-15.0 mg/lb body weight every 12 hours. Duration: Treatment with Clindamycin Hydrochloride Oral Drops is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen. Dosage Schedule: Oral Solution Clindamycin Hydrochloride Oral Drops, administer 2-6 mL/10 lbs body weight every 12 hours. Cats: Infected Wounds, Abscesses and Dental Infections 5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition. Duration: Treatment with Clindamycin Hydrochloride Oral Drops may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen. Dosage Schedule: Clindamycin Hydrochloride Oral Drops, to provide 5.0 mg/lb, administer 1 mL/5 lbs body weight once every 24 hours; to provide 15.0 mg/lb, administer 3 mL/5 lbs body weight once every 24 hours.

ORAL

ZydaClin™ ​ ​

Dogs: Infected Wounds, Abscesses, and Dental Infections Oral: 2.5-15.0 mg/lb body weight every 12 hours Duration: Treatment with Clindamycin Hydrochloride Tablets may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen. Dosage Schedule Tablets Clindamycin Hydrochloride Tablets 25 mg, administer 1-6 tablets every 12 hours for each 10 pounds of body weight. Clindamycin Hydrochloride Tablets 75 mg, administer 1-6 tablets every 12 hours for each 30 pounds of body weight. Clindamycin Hydrochloride Tablets 150 mg, administer 1-6 tablets every 12 hours for each 60 pounds of body weight. Dogs: Osteomyelitis Oral: 5.0-15.0 mg/lb body weight every 12 hours Duration: Treatment with Clindamycin Hydrochloride Tablets is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen. Dosage Schedule Tablets Clindamycin Hydrochloride Tablets 25 mg, administer 2-6 tablets every 12 hours for each 10 pounds of body weight. Clindamycin Hydrochloride Tablets 75 mg, administer 2-6 tablets every 12 hours for each 30 pounds of body weight. Clindamycin Hydrochloride Tablets 150 mg, administer 2-6 tablets every 12 hours for each 60 pounds of body weight.

ORAL

Clindamycin Hydrochloride Tablets

Dogs: Infected Wounds, Abscesses, and Dental Infections Oral: 2.5-15.0 mg/lb body weight every 12 hours. Duration: Treatment with clindamycin hydrochloride products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen. Dosage Schedule: Tablets CLINTABS 25 mg, administer 1-6 tablets every 12 hours for each 10 pounds of body weight. CLINTABS 75 mg, administer 1-6 tablets every 12 hours for each 30 pounds of body weight. CLINTABS 150 mg, administer 1-6 tablets every 12 hours for each 60 pounds of body weight. Dogs: Osteomyelitis Oral: 5.0-15.0 mg/lb body weight every 12 hours. Duration: Treatment with clindamycin hydrochloride is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen. Dosage Schedule: Tablets CLINTABS 25 mg, administer 2-6 tablets every 12 hours for each 10 pounds of body weight. CLINTABS 75 mg, administer 2-6 tablets every 12 hours for each 30 pounds of body weight. CLINTABS 150 mg, administer 2-6 tablets every 12 hours for each 60 pounds of body weight.

ORAL

CLINTABS® (clindamycin hydrochloride tablets)

Dogs: Infected Wounds, Abscesses, and Dental Infections Oral: 2.5-15.0 mg/lb body weight every 12 hours. Duration: Treatment with clindamycin hydrochloride products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen. Dosage Schedule: Tablets ZydaClin Tablets 25 mg, administer 1-6 tablets every 12 hours for each 10 pounds of body weight. Dogs: Osteomyelitis Oral: 5.0-15.0 mg/lb body weight every 12 hours. Duration: Treatment with clindamycin hydrochloride is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen. Dosage Schedule: Tablets ZydaClin Tablets 25 mg, administer 2-6 tablets every 12 hours for each 10 pounds of body weight.

ORAL

ZydaClin™ Tablets (clindamycin hydrochloride tablets)